XEFO

Hikma
Lornoxicam
Action
Xefo is a potent new non-steroidal anti-inflammatory
drug (NSAID) with antirheumatic and strong analgesic properties originally developed by Nycomed
Pharmaceuticals. Xefo is rapidly and completely
absorbed from the gastrointestinal tract with peak
plasma levels occuring within half an hour after oral
administration. Unlike other oxicam drugs, Xefo is
characterized by its short half-life which is 4 hours.

NaCI, 5% dextrose (glucose) and Ringers solution.

Dosage in patients with impaired renal and hepatic
function: the recommended maximum daily dose is
12mg to be given in divided doses.
Contraindications
Known hypersensitivity to Lornoxicam or any of the
excipients, peptic ulcer including those associated
with bleeding, and liver cirrhosis, haemorrhagic diathesis, blood coagulation disorders or at operations
bearing risks of bleeding or incomplete haemostasis, cerebral haemorrhage, severely impaired heart
function and moderately to severely impaired renal
function. Like other NSAIDs, Lornoxicam is contraindicated in asthmatic patients in whom attacks of
asthma, urticaria or acute rhinitis have been precipitated by aspirin or other NSAIDs.

Indications
Xefo Is indicated for the relief of mild to moderate
pain and inflammation in rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, painful post-traumatic and post-operative inflammation and swelling
(e.g. following dental surgery), painful syndromes
of vertebral column (e.g. low back pain) and acute
Warnings
lumbo sciatica.
There are no adequate and well-controlled studies
Dosage and administration
in pregnant women.
Mild to moderate pain associated with inflamma- Safety of the use of Lornoxicam during pregnancy,
tion: the recommended dosage is 8-16mg/day to be lactation and in patients under 18 years has not yet
given in 2-3 divided doses.
been established.
Rheumatic joint diseases: the recommended dosage is 12-16mg/day to be given in 2-3 divided Precautions
doses. In long-term therapy, Moderate postopera- Lornoxicam should be used cautiously in patients
tive pain: Xefo should be given either I.V. or I.M. in with a history of gastrointestinal disease or bleeddoses of 8mg, and the daily dose should not exceed ing, patients with severe heart failure, patients with
16mg in general. In some patients a further 8mg severe hepatic or renal disease and in patients with
given within the first 24 hours could be needed, systemic lupus erythematosus.
increasing the maximal allowed dose on the first Interactions
treatment day to 24mg, a dose higher than doctor Caution should be exercised in patients who are takrecommendation will not increase the effect of Xefo ing the following:
but may on the contrary cause side effects.
Diuretics - as diuretic effect might be decreased
The solution for injection is prepared by dissolving especially loop diuretics.
the content of one vial in water for injection from the Anticoagulant - as the bleeding time might be proaccompanying ampoule, immediately prior to use.
longed.
The time for injection should be at least over 15 sec- Oral antidiabetic - as the hypoglycemic effect might
onds and 5 seconds for I.V. and I.M., respectively.
be increased.
N.B: Lornoxicam has shown compatibility with 0.9% Beta blockers, lithium, cimetidine.

ACE Inhibitors - as the effect of the ACE-inhibitor

might be decreased.
Other NSAIDs - as the risk of adverse reactions
might be increased.
Like other NSAIDs, Lornoxicam may elevate
Digoxin, Methotrexate, and Cyclosporines serum
levels, so caution should be exercised.
Side effects
Lornoxicam is generally well tolerated. The common
side effects are GI upset, dyspepsia and injection site
reactions (pain, redness, stinging, tension). In rare
cases, some adverse effects have been reported such
as headache, dizziness, GI disorders like nausea and
vomiting, hematological disorders like anemia, dermatological disorders like itching and allergic skin reactions, perception disorders like tingling, visual disturbances and in isolated cases hematological disturbances, weight gain and disturbances in urine output.
Overdosage
There is no specific antidote. In case of overdose,
discontinue the administration of the medicament
and emptying the stomach via induction of emesis
(in alert patients only) or gastric lavage should be
exercised followed by the administration of activated
charcoal and instituting symptomatic and other supportive treatment as necessary.
Presentation
Tablets
Xefo 4mg:
Xefo 8mg:

Lornoxicam 4mg/ tablet

Lornoxicam 8mg/ tablet

Vials
Xefo:Lornoxicam (lyophilized) 8mg/2ml*
*after reconstitution.